The IPO Buzz: Parabilis Medicines (PBLS) Prices Upsized IPO at $20 – Above Range & Stock Pops

Let’s do this again: Cancer biotech Parabilis Medicines (PBLS) upsized its IPO at pricing to 33.5 million shares – up from 33.33 million shares – and priced the deal at $20.00 - $1.00 above the top of its range – to raise $670 million on Tuesday night, June 9, 2026. It was the IPO’s second upsizing of the day. Early Tuesday morning, Parabilis Medicines (PBLS) increased its IPO..

Read more June 10, 2026

IPO Calendar

Company Symbol proposed Lead Managers Shares (Millions) Price Low Price High Est. $ Volume Expected to Trade SCOOP Rating Rating Change
Forbright FRBT Goldman Sachs/J.P. Morgan/Barclays/Wells Fargo Securities/Piper Sandler/TD Securities/Santander/Centerview Partners 7.9 18.00 18.00 $ 142.2 mil 6/11/2026 Priced S/O S/O
Space Exploration Technologies SPCX Goldman Sachs/Morgan Stanley/BofA Securities/Citigroup/J.P. Morgan/Barclays/Deutsche Bank Securities/RBC Capital Markets/UBS Investment Bank/Wells Fargo Securities/Allen & Company/Cantor/Needham & Company/Raymond James/Societe Generale/Stifel/William Blair/BTG Pactual/ING/Macquarie Capital/Mirae Asset Securities/Mizuho/Santander 555.6 135.00 135.00 $ 75000.0 mil 6/12/2026 Friday S/O S/O
MetaOptics (Uplisting) MOT Roth Capital Partners/The Benchmark Company 3.0 5.00 7.00 $ 18.0 mil 6/15/2026 Week of S/O S/O
Read more

Last 100 IPOs - June 10, 2026

Number of IPOs priced : 100
Number Up: 52
Number Down: 46
Number Unchanged: 2
Percentage Change From Issue Price: 6.70%
Percentage Change for The Nasdaq Composite 35.22%

2026 IPO Scorecard - June 10, 2026

Number of IPOs priced (Excluding 108 units) : 81
Number Up: 42
Number Down: 37
Number Unchanged: 2
Total Return From Issue Price: 5.37%
The Nasdaq Composite Index YTD % Change 35.22%